Bordeaux, France (June 8, 2021) – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced that it has been chosen to present at the 66th annual ASAIO conference, which will take place on June 10 -12 at the Hilton DC Hotel in Washington, DC.
The First In Human implantation of the ICOMS FLOWMAKER® is assured following this financing.
FineHeart breaks new ground with successful removal of the ICOMS FLOWMAKER® in a 90-day in-vivo trial
Towards a new standard for device indication: Implantation for temporary or permanent use.
Wireless Transcutaneous Energy Transfer (TET) System for powering its ICOMS FLOWMAKER® Heart Pump.
A major step and a critical milestone achieved prior to First In Human clinical trials.
FineHeart Achieves Milestone For its Miniaturized Heart Pump Technology with Successful Completion of 30-Day Preclinical Study…
FineHeart was delighted to host its ICOMS FLOWMAKER® webcast on June 25th 2020 with leading US cardiac KOLs Professors Mandeep Mehra and Frank Pagani.
FineHeart, a French medical device company, today announced the success of a seven-day preclinical study to evaluate its Implantable Cardiac Output Management System (ICOMS FLOWMAKER®), the first fully Intra-Ventricular Flow Accelerator synchronized to the native heartbeat to restore natural heart pumping capacity.
Thank you to Mary Stuart for this great article in Medtech Strategist. If you want to learn more about FineHeart and why the ICOMS FLOWMAKER® will become the new standard in severe Heart Failure treatment, here it is !
For the second year, 100 brevets.tech reveals its ranking of the most innovative startup in France. FineHeart is one of them, and ranks in the top 20 !
The Emerging Medtech Summit is held annually at The Ritz-Carlton Laguna Niguel in Dana Point CA. The event has a single mission: to bring together the most innovative medtech startups, active investors, and strategic buyers to deal-make and collaborate about the future of Medtech industry.